Article citationsMore>>

Xiao, Z., Hao, Y., Liu, B., et al. (2002) Indirubin and Meisoindigo in the Treatment of Chronic Myelogenous Leukemia in China. Leukemia & Lymphoma, 43, 1763-1768. https://doi.org/10.1080/1042819021000006295

has been cited by the following article:

• TITLE: Effect of N’-Acetylindirubin on Proliferation, Apoptosis and Cell Cycle in Acute Myeloid Leukemia HL-60 Cells

  AUTHORS: Tang Li, Li Yu

  KEYWORDS: N’-Acetylindirubin, HL-60, Apoptosis, Cell Cycle

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.6 No.5, May 31, 2018

  ABSTRACT: Acute promyelocytic leukemia (APL) is a severe type of acute leukemia and the prognosis of patients was poor. Indirubin is the active constituent of the traditional Chinese medicine qingdai and an indoline anti-tumor drug. N’-Acetylindirubin is a novel indirubin derivative with better curative effect and less side effect. In this study, the effects of N’-Acetylindirubin on proliferation, apoptosis and cell cycle of acute myeloid leukemia cell line HL-60 was examined. The results demonstrated that N’-Acetylindirubin significantly induced apoptotic cell death in a dose and time-dependent manner and arrested cell cycle in G2/M in HL-60 cells. N’-Acetylindirubin also suppressed cyclin D1. This study suggests that N’-Acetylindirubin may serves as a potential chemopreventive agent for acute promyelocytic leukemia.